Glutathione-S-transferase-pi (GST-pi) expression in renal cell carcinoma

  • Kaprilian C
  • Horti M
  • Kandilaris K
  • et al.
N/ACitations
Citations of this article
8Readers
Mendeley users who have this article in their library.

Abstract

Multidrug resistance correlates with unfavourable treatment outcomes in numerous cancers including renal cell carcinoma. The expression and clinical relevance of Glutathione-S-transferase-pi (GST-pi), a multidrug resistance factor, in kidney tumors remain controversial. We analyzed the expression of GST-pi in 60 formalin-fixed, paraffin-embedded renal cell carcinoma samples by immunohistochemistry and compared them with matched normal regions of the kidney. A significantly higher expression of GST-pi was observed in 87% of clear cell carcinoma and 50% of papillary subtypes. GST-pi expression did not correlate with tumor grade or patient survival. GST-pi is unlikely to be a prognostic factor for renal cell carcinoma. However, further studies with large number of samples are warranted to establish the role of GST-pi, if any, in intrinsic or acquired resistance of renal cell carcinoma to conventional treatments.

Cite

CITATION STYLE

APA

Kaprilian, C., Horti, M., Kandilaris, K., Skolarikos, A., Trakas, N., Kastriotis, I., & Deliveliotis, C. (2015). Glutathione-S-transferase-pi (GST-pi) expression in renal cell carcinoma. Journal of Kidney Cancer and VHL, 2(1), 25–29. https://doi.org/10.15586/jkcvhl.2015.22

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free